BYL719 + Fulvestrant
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Solid Tumors With an Alteration of the PIK3CA Gene
Conditions
Advanced Solid Tumors With an Alteration of the PIK3CA Gene, Estrogen Receptor Positive Breast Cancer
Trial Timeline
Oct 5, 2010 → Apr 16, 2020
NCT ID
NCT01219699About BYL719 + Fulvestrant
BYL719 + Fulvestrant is a phase 1 stage product being developed by Novartis for Advanced Solid Tumors With an Alteration of the PIK3CA Gene. The current trial status is completed. This product is registered under clinical trial identifier NCT01219699. Target conditions include Advanced Solid Tumors With an Alteration of the PIK3CA Gene, Estrogen Receptor Positive Breast Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01219699 | Phase 1 | Completed |
Competing Products
20 competing products in Advanced Solid Tumors With an Alteration of the PIK3CA Gene